Description
AbbVie’s 460% Secret: Patent Tricks and Pipeline Gold!
AbbVie just turned a patent cliff into a gold mine. Investors who held the stock through the last decade have seen gains of 460%, a feat few thought possible when Humira’s composition of matter patent expired back in 2016. Rather than suffer a catastrophic drop, the company delayed biosimilar entry through a dense patent-thicket strategy and used excess cash flow from Humira’s prolonged dominance to fund next-generation autoimmune drugs Skyrizi and Rinvoq. Today, those drugs are expected to generate $31 billion in 2026, outpacing Humira at its peak. With shares now trading at a forward P/E of 16.3x and a dividend yield of 3.1%, investors are asking whether Merck and Bristol Myers Squibb (NYSE:BMY) can replicate this playbook. With Keytruda’s exclusivity ending in 2028 and Bristol Myers facing loss of exclusivity (LOE) for drugs making up 75% of revenue by 2031, the stakes are high.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
